# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): February 9, 2023

dxcm-20230209\_g1.jpg

# DEXCOM, INC.

(Exact Name of the Registrant as Specified in Its Charter)

000-51222

(Commission File Number)

**Delaware**(State or Other Jurisdiction of Incorporation)

33-0857544

(I.R.S. Employer Identification No.)

	6340 Sequence Drive, San Diego, CA 9212 ss of Principal Executive Offices, Including 2		
(Deci-	(858) 200-0200	(Code)	
, 0	strant's Telephone Number, Including Area ame or Former Address, if Changed Since	,	
Check the appropriate box below if the Form 8-K filing is interpretations (see General Instruction A2. below):		. ,	
☐ Written communications pursuant to Rule 425 under the	e Securities Act (17 CFR 230.425)		
☐ Soliciting material pursuant to Rule 14a-12 under the E	xchange Act (17 CFR 240.14a-12)		
☐ Pre-commencement communications pursuant to Rule	e 14d-2(b) under the Exchange Act (17 CFR	240.14d-2(b))	
☐ Pre-commencement communications pursuant to Rule	: 13e-4(c) under the Exchange Act (17 CFR	240.13e-4(c))	
Securi	ties registered pursuant to Section 12(b) o	f the Act:	
Title of Each Class	Trading Symbol(s)	Name of Each Exchange on Which Registered	
Common Stock, \$0.001 Par Value Per Share	DXCM	Nasdaq Global Select Market	
ndicate by check mark whether the registrant is an emergin chapter) or Rule 12b-2 of the Securities Exchange Act of 19	ng growth company as defined in Rule 405 34 (§240.12b-2 of this chapter).	of the Securities Act of 1933 (§230.405 of this	
		Emerging growth company	
f an emerging growth company, indicate by check mark if the evised financial accounting standards provided pursuant to		ended transition period for complying with any new or	

#### ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On February 9, 2023, DexCom, Inc. ("Dexcom") issued a press release announcing its financial results for the quarter and year ended December 31, 2022 and certain other information. A copy of the press release is furnished as Exhibit 99.1 to this report.

The information in this Item 2.02, including Exhibit 99.1 hereto, is furnished shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of Dexcom under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.

#### ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

#### (d) Exhibits.

Number	Description
<u>99.1</u>	Press release dated February 9, 2023 announcing the financial results for the quarter and year ended December 31, 2022 and certain other information
104	Cover Page Interactive Data File (formatted as Inline XBRL)

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

### DEXCOM, INC.

By: /s/ JEREME M. SYLVAIN

Jereme M. Sylvain
Executive Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)

Date: February 9, 2023